FAB Fusion Antibodies plc

0.0560USD4.250 GBp · LSE0.00%Mkt Cap: 7.00M USDP/E: —

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of …

Key Statistics

Company
Market Cap7.00M USD
Enterprise Value6.06M USD
Revenue (TTM)2.78M USD
Gross Profit1.62M USD
Net Income (TTM)-1.51M USD
Revenue/Share0.02 USD
Last Price0.0560 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees27
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BDQZGK16
Valuation
P/E (Trailing)—
P/E (Forward)-4.72
PEG—
EV/EBITDA-4.35
EV/Revenue2.18
P/S2.52
P/B3.27
EPS (TTM)-0.01 USD
EPS (Forward)-0.01 USD
52W Range
0.000021% of range0.2634
52W High0.2634 USD
52W Low0.0000 USD
Profitability
Gross Margin58.34%
Oper. Margin-52.56%
EBITDA Margin-50.10%
Profit Margin-54.45%
ROE-70.84%
ROA-42.15%
ROIC-134.29%
ROCE-64.86%
Growth
Revenue Growth67.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.47M USD
CapEx (TTM)79.01K USD
FCF Margin-35.34%
FCF Yield-14.02%
Net Debt-937.59K USD
Net Debt/EBITDA0.67
Net Debt/FCF—
Balance Sheet
Debt/Equity0.20
Current Ratio2.82
Quick Ratio2.08
Book Value/Sh0.02 USD
Cash/Share0.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.125.16M
Float110.05M
Insiders12.16%
Institutions29.00%
Technical
SMA 500.1111 (-49.6%)
SMA 2000.1508 (-62.9%)
Beta1.41
S&P 52W Chg12.08%
Avg Vol (30d)884.36K
Avg Vol (10d)884.09K
Technical Indicators
RSI (14)20.2
MACD-1.0539
MACD Signal-1.1308
MACD Hist.+0.0768
BB Upper0.0890 USD
BB Middle0.0677 USD
BB Lower0.0464 USD
BB Width62.88%
ATR (14)0.0113 USD
Vol Ratio (20d)0.04x

About Fusion Antibodies (LON: FAB)

›

Fusion Antibodies (LON: FAB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.

The shares were at 4.250 GBp on 19 November 2026, down 67.9% over 52 weeks.

Its market capitalisation is 5.32M GBP.

Fusion Antibodies reports return on equity of -70.8%, an operating margin of -52.6% and revenue up 67.8% year over year.

It holds more cash than debt, a net cash position of 712.00K GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.